JP2022521410A5 - - Google Patents

Info

Publication number
JP2022521410A5
JP2022521410A5 JP2021549435A JP2021549435A JP2022521410A5 JP 2022521410 A5 JP2022521410 A5 JP 2022521410A5 JP 2021549435 A JP2021549435 A JP 2021549435A JP 2021549435 A JP2021549435 A JP 2021549435A JP 2022521410 A5 JP2022521410 A5 JP 2022521410A5
Authority
JP
Japan
Prior art keywords
antigens
vaccine composition
composition according
antigen
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019367 external-priority patent/WO2020172635A1/en
Publication of JP2022521410A publication Critical patent/JP2022521410A/ja
Publication of JP2022521410A5 publication Critical patent/JP2022521410A5/ja
Priority to JP2025056539A priority Critical patent/JP2025098224A/ja
Pending legal-status Critical Current

Links

JP2021549435A 2019-02-21 2020-02-21 最適化されたワクチン組成物およびその製造方法 Pending JP2022521410A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025056539A JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962808760P 2019-02-21 2019-02-21
US62/808,760 2019-02-21
US201962817902P 2019-03-13 2019-03-13
US62/817,902 2019-03-13
PCT/US2020/019367 WO2020172635A1 (en) 2019-02-21 2020-02-21 Optimized vaccine compositions and methods for making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025056539A Division JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Publications (2)

Publication Number Publication Date
JP2022521410A JP2022521410A (ja) 2022-04-07
JP2022521410A5 true JP2022521410A5 (enExample) 2023-09-07

Family

ID=72145134

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549435A Pending JP2022521410A (ja) 2019-02-21 2020-02-21 最適化されたワクチン組成物およびその製造方法
JP2025056539A Pending JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025056539A Pending JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Country Status (5)

Country Link
US (1) US20220088175A1 (enExample)
EP (2) EP3927372A4 (enExample)
JP (2) JP2022521410A (enExample)
CN (1) CN113747915A (enExample)
WO (1) WO2020172635A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217714B (zh) * 2022-10-14 2024-03-15 华中农业大学 一种全猪源pedv单克隆抗体及其抗原表位
WO2024102923A1 (en) * 2022-11-09 2024-05-16 Centivax, Inc. Low dose vaccine compositions
CN121729242A (zh) * 2023-04-20 2026-03-24 森蒂瓦克斯公司 疫苗组合物及其用途
CN119219767B (zh) * 2023-06-29 2025-05-27 华中农业大学 两株全猪源pedv单克隆中和抗体及其用途
WO2025235418A1 (en) * 2024-05-05 2025-11-13 National Health Research Institutes Virus-like particle, preparation method thereof, and use thereof in preparing vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425611B2 (en) * 2003-03-28 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use
EP2023952B1 (en) * 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN103826657A (zh) * 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
AU2012271336B2 (en) * 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
US9884893B2 (en) * 2012-05-21 2018-02-06 Distributed Bio, Inc. Epitope focusing by variable effective antigen surface concentration
JP2018504412A (ja) * 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
WO2016205389A1 (en) * 2015-06-15 2016-12-22 Emory University Multivalent enterovirus vaccine compositions and uses related thereto
WO2018073340A1 (en) * 2016-10-19 2018-04-26 Redbiotec Ag Influenza virus vaccine
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신

Similar Documents

Publication Publication Date Title
JP2019526580A5 (enExample)
Young et al. Virus-like particles: designing an effective AIDS vaccine
Van Ginkel et al. Vaccines for mucosal immunity to combat emerging infectious diseases
O'Hagan et al. Recent developments in adjuvants for vaccines against infectious diseases
JP2009539965A5 (enExample)
JP2010516763A5 (enExample)
JP2022172244A5 (enExample)
JP2009516529A5 (enExample)
JP2017515508A5 (enExample)
JP2009511084A5 (enExample)
JP2006141398A5 (enExample)
Rezaei et al. Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials
JP2003526676A (ja) ワクチン用のアジュバント
JP2006504644A5 (enExample)
US6641816B1 (en) Use of poxviruses as enhancer of specific immunity
JP2019534003A5 (enExample)
JP2022514759A5 (enExample)
JP2024520730A5 (enExample)
JP2009501901A5 (enExample)
Omoniyi et al. Designing a multi-epitope vaccine against the Lassa virus through reverse vaccinology, subtractive proteomics, and immunoinformatics approaches
Zhang et al. Polymer–protein core–shell nanoparticles for enhanced antigen immunogenicity
JP2023099200A (ja) アジュバントおよび該アジュバントを含むワクチン
JP2019534242A5 (enExample)
JP2023548205A5 (enExample)
MX2024014303A (es) Vacuna multivalente contra paramyxovirus y usos de la misma